Enhanced anti-tumor efficacy of berberine-loaded mesoporous polydopamine nanoparticles for synergistic chemotherapy and photothermal therapy

[Display omitted] The development of innovative therapeutic strategies that combine multiple treatment modalities is essential for effective cancer therapy. In this study, we engineered berberine (BER)-loaded mesoporous polydopamine (MPDA) nanoparticles (BER-MPDA) to enhance anti-tumor efficacy thro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of pharmaceutics 2024-12, Vol.670, p.125151, Article 125151
Hauptverfasser: Ding, Qian, Shang, Jinlu, Yang, Liuxuan, Deng, Li, Wu, Siqiong, Chen, Jing, Yang, Jing, Wang, Ke, Li, Chunhong, Chen, Junyan, Zhou, Meiling
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] The development of innovative therapeutic strategies that combine multiple treatment modalities is essential for effective cancer therapy. In this study, we engineered berberine (BER)-loaded mesoporous polydopamine (MPDA) nanoparticles (BER-MPDA) to enhance anti-tumor efficacy through synergistic chemotherapy and photothermal therapy (PTT). The mesoporous structure of MPDA allowed for a high loading capacity of BER, a natural isoquinoline alkaloid with known anticancer properties. Upon near-infrared laser irradiation, BER-MPDA exhibited marked photothermal conversion efficiency, leading to effective tumor cell ablation. Both in vitro and in vivo experiments indicated that the combined treatment of BER-MPDA with near-infrared laser irradiation resulted in superior tumor inhibition compared to monotherapy. The synergistic effect was attributed to the enhanced cellular uptake and the simultaneous induction of chemo- and photothermal cytotoxicity. Our findings suggest that BER-MPDA represents a promising platform for multimodal cancer therapy, offering a potent approach to overcoming the limitations of conventional chemotherapy and PTT.
ISSN:0378-5173
1873-3476
1873-3476
DOI:10.1016/j.ijpharm.2024.125151